Kate Lathrop, MD discuss one of the high impact, clinically relevant, clinical trial, the HER2CLIMB-05 trail that were presented at the San Antonio Breast Cancer Symposium 2025.
Video: https://medicaldigest.org/scientific-contents/interview:program-directors-choice-sabcs2025-part-3-adding-tucatinib-first-line-maintenance-therapy-delayed-disease-progression-her2-positive-metastatic-breast-cancer-her2climb-05-trial